Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease

Objectives: To determine whether the rehospitalisation and primary care requirements of infants with chronic lung disease (CLD) during the first two years after birth were influenced by a requirement for supplementary oxygen after discharge from the neonatal intensive care unit. Methods: Review of records from both the hospital and general practitioner. Patients: 235 infants, median gestational age 27 (range 22–31) weeks, 88 of whom were receiving supplementary oxygen when discharged home. Results: Overall, the infants required a median of 2 (range 0–20) admissions per patient, 8 (0–41) outpatient attendances, 13 (0–76) contacts with the general practitioner, and 17 (0–169) consultations with other primary healthcare professionals. The home oxygen patients required significantly more and longer admissions (p < 0.01) and more outpatient attendances (p < 0.05). The total cost of care per infant of the home oxygen group was greater (p < 0.001); this reflected higher costs for hospital stay (p < 0.01), total inpatient care (p < 0.01), and primary care drugs (p < 0.01). Conclusion: Despite routine use of antenatal steroids and postnatal surfactant, certain patients with CLD, particularly those who receive home oxygen treatment, show high rates of utilisation of health service resources after discharge from the neonatal care unit.

[1]  A. Greenough,et al.  Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection , 2001, Archives of disease in childhood.

[2]  Tracey,et al.  Authors , 2001, Brain Research.

[3]  A. Greenough Breathing patterns, oxygen and carbon dioxide levels during infancy , 2000, Acta paediatrica.

[4]  G. Dimitriou,et al.  Chronic respiratory morbidity following premature delivery – prediction by prolonged respiratory support requirement? , 1999, European Journal of Pediatrics.

[5]  C. Poets When do infants need additional inspired oxygen? A review of the current literature , 1998 .

[6]  W. Dankner Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis , 1997, Pediatrics.

[7]  M. Hack,et al.  Hospitalization as a measure of morbidity among very low birth weight infants with chronic lung disease. , 1996, The Journal of pediatrics.

[8]  C. Poets,et al.  Hypoxaemia in infants with bronchopulmonary dysplasia. , 1993, Pediatrics.

[9]  A. Ohlsson,et al.  Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. , 1988, Pediatrics.

[10]  A. Rosenberg,et al.  Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia. , 1987, American journal of diseases of children.

[11]  R. Mellins,et al.  Bronchopulmonary dysplasia. Unresolved neonatal acute lung injury. , 1985, The American review of respiratory disease.

[12]  F. Accurso,et al.  Outpatient management and follow-up of bronchopulmonary dysplasia. , 1984, Clinics in perinatology.

[13]  A. Orgill,et al.  Growth and development of very low birthweight infants recovering from bronchopulmonary dysplasia. , 1983, Archives of disease in childhood.

[14]  M. Stahlman,et al.  SEVERE BRONCHOPULMONARY DYSPLASIA: A RETROSPECTIVE REVIEW , 1983, Acta paediatrica Scandinavica.

[15]  T. Markestad,et al.  Growth and development in children recovering from bronchopulmonary dysplasia. , 1981, The Journal of pediatrics.

[16]  M. Palta,et al.  Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project. , 1998, The Journal of pediatrics.

[17]  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. , 1998, Pediatrics.